The patients did not come in for a sexually transmitted infection. They came in because their knee hurt.
That is the finding buried in new CDC surveillance data from Alaska, and it is the reason the state's increase in a rare gonorrhea complication is worth attention well outside Alaska. Of 35 people identified with disseminated gonococcal infection during 2023 and 2024, 28 of them, or 80 percent, had no mucosal symptoms. No burning with urination. No discharge. Nothing that would prompt anyone, patient or clinician, to think about gonorrhea.
The trigger for the investigation was a single clinician noticing a pattern. In April 2024, an infectious disease physician told the Alaska Section of Epidemiology that unusual numbers of patients were turning up at Anchorage emergency departments with joint pain that turned out to be gonococcal.
The numbers that followed are stark. DGI accounted for 0.35 percent of reported gonorrhea cases in Alaska in 2023, or 8 of 2,289. In 2024, it accounted for 1.3 percent, or 27 of 2,079. The total gonorrhea count went down. The severe complication went up almost fourfold.
What Disseminated Gonococcal Infection Actually Is
Gonorrhea usually stays where it starts, in the genital tract, throat, or rectum. Disseminated infection is what happens when the bacteria breach that local site, enter the bloodstream and travel.
CDC describes DGI as "a rare but serious complication" of Neisseria gonorrhoeae that can result in severe illness or death, occurring in under 1 percent of reported cases.
The presentation is joint and skin disease rather than urinary. Septic arthritis, in which a joint becomes infected, swollen, and intensely painful. Asymmetric polyarthralgia, meaning pain across several joints in an uneven pattern. Tenosynovitis, inflammation of tendon sheaths, often in the wrists, hands or ankles. And a characteristic scatter of skin lesions, typically small pustular or hemorrhagic spots on the limbs.
In the Alaska group, 21 patients, or 60 percent, had septic arthritis, and three, or 9 percent, developed endocarditis, an infection of the heart valves. Median patient age was 36, 51 percent were male, and 37 percent had a documented substance use disorder. Alaska's own bulletins report that roughly nine in ten patients required hospitalization, that many needed invasive procedures, and that the state documented a fatal case in 2025.
A multistate analysis of 274 DGI cases across 13 states during 2020 to 2022 found a case fatality rate of 2.2 percent.
Why This Reads as a Detection Problem
Here is the arithmetic that matters. Disseminated infection is what untreated gonorrhea becomes. It does not appear in someone who was tested, diagnosed and treated. Alaska's epidemiology bulletin describes the pathway plainly as "untreated infection leading to disseminated infection."
So a rise in DGI is, mechanically, a signal that infections are going undetected long enough to invade the bloodstream. The 80 percent figure explains how. If four in five patients never developed genital symptoms, then symptom-driven testing was never going to find them. They had no reason to seek care and their clinicians had no reason to swab.
Alaska health officials have suggested that gonococcal strains circulating in the state may be both more likely to disseminate and more likely to be asymptomatic on initial infection, a combination that would produce exactly this pattern. That remains a hypothesis under investigation, and the state has not identified a single linking network among the cases.
Two other factors sit alongside it, and none of the three excludes the others. Screening reach determines whether asymptomatic infections are found at all, and screening in the United States is concentrated in specific groups rather than offered broadly. And antimicrobial resistance in N. gonorrhoeae has narrowed treatment options over two decades, which matters for whether treatment works when it is given.
This is not unique to Alaska. Minnesota reported a roughly fourfold increase in gonococcal infections from normally sterile sites in 2024 and used whole genome sequencing to investigate. CDC built a national DGI surveillance system in 2020 in response to rising reports of cases and clusters.
Who Should Be Tested and When
Because the symptoms that usually prompt testing were absent in most of these patients, routine screening carries the weight.
CDC recommends annual gonorrhea and chlamydia screening for sexually active women under 25 and for older women with risk factors such as a new partner, multiple partners or a partner with an STI. It recommends at least annual screening for sexually active gay, bisexual and other men who have sex with men, more frequently for some, and screening for anyone with HIV. Pregnancy screening is standard.
Two practical points get missed often. Testing has to match exposure, so a urine test alone will not detect a throat or rectal infection, and extragenital sites are precisely where asymptomatic infections hide. And a partner's diagnosis is reason to be tested regardless of how you feel.
Anyone with a swollen, hot, painful joint, particularly with a fever or a rash of small spots on the arms or legs, should seek medical care and mention any possible STI exposure. Naming it is what gets the right test ordered. Septic arthritis of any cause is urgent, because an infected joint can be permanently damaged within days.
Gonorrhea is curable with the recommended antibiotic regimen, and DGI is treatable, but treatment for disseminated disease is considerably more involved than for uncomplicated infection, often requiring hospitalization and intravenous therapy.
What Happens Next
Alaska's investigation continues, including work on whether specific circulating strains carry a greater tendency to disseminate. Genomic investigations in Minnesota and elsewhere are pursuing the same question, and the answer would clarify whether this is a pathogen change, a detection failure, or both.
For readers, the useful takeaway is not alarm about a rare complication. It is that the strongest predictor of a severe outcome here was not having symptoms, which turns routine screening from a formality into the actual intervention.
The confirmed finding is a rise in disseminated gonococcal infections in Alaska across two years, with most patients showing no genital symptoms. The people most affected are sexually active adults whose infections go undetected, and Alaska's data suggest that includes people with substance use disorders who face additional barriers to routine care. The most reasonable action is asking a clinician whether you are due for screening and whether the test covers all relevant sites. The central uncertainty is whether this reflects a changing organism, a gap in detection, or a combination of the two.
Frequently Asked Questions
What did CDC report? Alaska identified 35 disseminated gonococcal infection cases during 2023 and 2024. DGI accounted for 0.35 percent of gonorrhea cases in 2023 and 1.3 percent in 2024.
What is disseminated gonococcal infection? It occurs when gonorrhea bacteria enter the bloodstream and spread from the original site, causing joint, skin and sometimes heart valve infection. It affects under 1 percent of reported gonorrhea cases.
What are the symptoms? Painful swollen joints, pain across several joints in an uneven pattern, tendon sheath inflammation, and small pustular or bloody-looking skin spots, often with fever.
Why did most patients have no genital symptoms? Eighty percent lacked mucosal symptoms, meaning nothing prompted them or their clinicians to consider gonorrhea before the infection had already spread.
Is it treatable? Yes. Gonorrhea is curable with recommended antibiotics, though disseminated infection usually requires hospitalization and intravenous treatment.
Who should be screened? Sexually active women under 25, older women with risk factors, sexually active men who have sex with men, people with HIV, and anyone whose partner has been diagnosed.
Does a urine test cover everything? No. Throat and rectal infections require swabs from those sites, and those are common locations for infections without symptoms.
